论文部分内容阅读
本文报告73例口服缓释钾片临床观察结果。第1组63例血清钾浓度正常者因服双氢克尿塞或速尿等排钾利尿剂同时服缓释钾片,用药后1至2周平均血清钾浓度仍保持在正常水平。第2组10例为低血钾症,单服缓释钾片后1至2周平均血清钾浓度能提高到正常水平。71例无消化道等副作用。观察结果说明缓释钾片作用确切,副作用小,为目前较理想的补钾剂型,但使用缓释钾片剂量应根据血浆钾浓度、尿量等决定。
This article reports 73 cases of oral sustained-release potassium clinical observations. The first group of 63 patients with normal serum potassium concentration due to taking hydrochlorothiazide or furosemide diuretics scheduled concurrent release of potassium tablets, the average serum potassium concentration after 1 to 2 weeks to maintain the normal level. The second group of 10 cases of hypokalemia, single oral sustained-release potassium tablets 1-2 weeks after the average serum potassium concentration can be increased to normal levels. 71 cases of gastrointestinal side effects. The results show that the exact effect of sustained release potassium tablets, side effects, as the current ideal potassium dosage form, but the use of sustained release potassium dose should be based on plasma potassium concentration, urine output and other decisions.